BriaCell Therapeutics Corp. Files 10-Q for Period Ending January 31, 2024

TL;DR

<b>BriaCell Therapeutics Corp. has filed its Q2 2024 10-Q report, detailing financial performance and operations for the period ending January 31, 2024.</b>

AI Summary

BriaCell Therapeutics Corp. (BCTXZ) filed a Quarterly Report (10-Q) with the SEC on March 18, 2024. BriaCell Therapeutics Corp. filed a 10-Q for the period ending January 31, 2024. The filing covers the second quarter of fiscal year 2024. The company's fiscal year ends on July 31st. BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp. The company is in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking BriaCell Therapeutics Corp., this filing contains several important signals. This 10-Q filing provides investors with an updated view of BriaCell's financial health and operational progress for the second quarter of fiscal year 2024. Understanding the details within this report is crucial for assessing the company's current standing and future prospects in the pharmaceutical sector.

Risk Assessment

Risk Level: — BriaCell Therapeutics Corp. shows moderate risk based on this filing. The company's financial performance and operational status are detailed in this 10-Q, but specific financial figures and growth metrics are not yet available in the provided text for a more precise risk assessment.

Analyst Insight

Review the full 10-Q filing for detailed financial statements, management discussion, and risk factors to make an informed investment decision.

Key Players & Entities

• BriaCell Therapeutics Corp. (company) — Filer and subject of the report.
• Ansell Capital Corp. (company) — Former name of BriaCell Therapeutics Corp.
• 2024-01-31 (date) — End of the reporting period.
• 2024-03-18 (date) — Filing date of the report.
• 2024-07-31 (date) — Fiscal year end.
• 2834 (industry) — Standard Industrial Classification for Pharmaceutical Preparations.

FAQ

Industry Context

BriaCell Therapeutics Corp. operates within the Pharmaceutical Preparations sector, focusing on the development and commercialization of drugs.

Regulatory Implications

As a publicly traded company, BriaCell Therapeutics Corp. is subject to SEC regulations and reporting requirements, including the filing of quarterly 10-Q reports.

What Investors Should Do

1. Thoroughly review the financial statements and management's discussion and analysis within the 10-Q.
2. Analyze the risk factors section for potential challenges and uncertainties facing the company.
3. Compare the current quarter's performance against historical data and industry benchmarks.

Key Dates

• 2024-01-31: End of Fiscal Q2 2024 — Reporting period end date for the 10-Q.
• 2024-03-18: Filing Date — Date the 10-Q was officially filed with the SEC.
• 2024-07-31: Fiscal Year End — Marks the end of BriaCell's annual fiscal year.

Year-Over-Year Comparison

This filing represents the 10-Q for the second quarter of fiscal year 2024, providing an update from previous filings.

Filing Documents

• form10-q.htm (10-Q) — 835KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-010354.txt (&nbsp;) — 4477KB
• bctx-20240131.xsd (EX-101.SCH) — 30KB
• bctx-20240131_cal.xml (EX-101.CAL) — 38KB
• bctx-20240131_def.xml (EX-101.DEF) — 180KB
• bctx-20240131_lab.xml (EX-101.LAB) — 260KB
• bctx-20240131_pre.xml (EX-101.PRE) — 226KB
• form10-q_htm.xml (XML) — 773KB

Financial Information

Part I. Financial Information 3 Item 1.

Financial Statements

Financial Statements 3 Condensed Consolidated Balance Sheets as of January 31, 2024 (unaudited) and July 31, 2023 (unaudited) 3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended January 31, 2024 4 Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three and Six Months ended January 31, 2024 5 Unaudited Condensed Consolidated Statement of Cash Flows for the Six Months ended January 31, 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures Regarding Market Risk

Quantitative and Qualitative Disclosures Regarding Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23

Other Information

Part II. Other Information 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 24

Signatures

Signatures 25 2 PART I-FINANCIAL INFORMATION Item 1. Financial Statements BRIACELL THERAPEUTICS CORP. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS January 31, 2024 July 31, 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 6,244,528 $ 21,251,092 Amounts receivable 30,145 18,873 Prepaid expenses 5,467,286 5,678,542 Total current assets 11,741,959 26,948,507 NON-CURRENT ASSETS: Investments 2 2 Equity investment in BC Therapeutics 281,655 - Intangible assets, net 207,431 215,068 Total non-current assets 489,088 215,070 Total assets $ 12,231,047 $ 27,163,577 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables $ 3,711,455 $ 1,123,739 Accrued expenses and other payables 212,870 677,718 Total current liabilities 3,924,325 1,801,457 NON-CURRENT LIABILITIES: Warrant liability 16,624,177 29,139,301 Total non-current liabilities 16,624,177 29,139,301 SHAREHOLDERS' DEFICIT: Share Capital of no par value - Authorized: unlimited at January 31, 2024 and July 31, 2023, Issued and outstanding: 15,981,726 shares January 31, 2024 and July 31, 2023, respectively 69,591,784 69,591,784 Share-based payment reserve 8,419,154 7,421,950 Accumulated other comprehensive loss ( 138,684 ) ( 138,684 ) Non-controlling Interest ( 244,418 ) - Accumulated deficit ( 85,945,291 ) ( 80,652,231 ) Total shareholders' deficit ( 8,317,455 ) ( 3,777,181 ) Total liabilities and shareholders' deficit $ 12,231,047 $ 27,163,577 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 BRIACELL THERAPEUTICS CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND SIX MONTHS ENDED JANUARY 31, 2024 (Unaudited) 2024 2023 2024 2023 Three months ended January 31, Six months ended January 31, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited)

View Full Filing

View this 10-Q filing on SEC EDGAR